chr6-112150513-C-T
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_001105206.3(LAMA4):c.2171G>A(p.Arg724Lys) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000886 in 1,593,550 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001105206.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LAMA4 | NM_001105206.3 | c.2171G>A | p.Arg724Lys | missense_variant, splice_region_variant | 17/39 | ENST00000230538.12 | NP_001098676.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LAMA4 | ENST00000230538.12 | c.2171G>A | p.Arg724Lys | missense_variant, splice_region_variant | 17/39 | 1 | NM_001105206.3 | ENSP00000230538.7 |
Frequencies
GnomAD3 genomes AF: 0.000670 AC: 102AN: 152170Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000804 AC: 202AN: 251370Hom.: 1 AF XY: 0.000891 AC XY: 121AN XY: 135868
GnomAD4 exome AF: 0.000909 AC: 1310AN: 1441380Hom.: 4 Cov.: 28 AF XY: 0.000907 AC XY: 652AN XY: 718520
GnomAD4 genome AF: 0.000670 AC: 102AN: 152170Hom.: 0 Cov.: 32 AF XY: 0.000538 AC XY: 40AN XY: 74328
ClinVar
Submissions by phenotype
Dilated cardiomyopathy 1JJ Uncertain:1Benign:3
Likely benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Mar 30, 2021 | LAMA4 NM_002290.4 exon 17 p.Arg717Lys (c.2150G>A): This variant has not been reported in the literature and is present in 0.1% (163/129082) of European alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/variant/6-112471715-C-T). This variant is present in ClinVar, with several labs classifying this variant as likely benign (Variation ID:44361). Evolutionary conservation and computational predictive tools suggest that this variant may not impact the protein. In summary, data on this variant suggests that this variant does not cause disease, but requires further evidence. Therefore this variant is classified as likely benign. - |
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Apr 21, 2022 | - - |
not provided Benign:4
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Likely benign, criteria provided, single submitter | research | Biesecker Lab/Clinical Genomics Section, National Institutes of Health | Jun 24, 2013 | - - |
Likely benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
not specified Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 26, 2017 | Although the R717K variant in the LAMA4 gene has not been published as pathogenic or been reported as benign to our knowledge, it has been reported as a variant of uncertain significance by another clinical laboratory in ClinVar (SCV000061006.3; Landrum et al., 2016), and has been reported as likely benign in the ClinSeq Project (Ng et al., 2013). This variant has been observed in 0.1-0.2% of alleles from individuals of European ancestry in large population cohorts (Lek et al., 2016; Exome Variant Server). The R717K variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Although this substitution occurs at a position conserved in mammals, in silico analysis predicts this variant likely does not alter the protein structure/function. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 18, 2015 | Variant classified as Uncertain Significance - Favor Benign. The p.Arg717Lys var iant in LAMA4 has been identified by our laboratory in 1 individual with DCM wit h LBBB and in 1 individual with a family history of ARVC. This variant has also been identified in 0.1% (92/66738) of European chromosomes by the Exome Aggregat ion Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs146868519). Comput ational prediction tools and conservation analysis suggest that the p.Arg717Lys variant may not impact the protein and 2 species (green sea turtle and tasmanian devil) carry a lysine (Lys) at this position suggesting this change may be tole rated. However, this information is not predictive enough to rule out pathogenic ity. This variant is located in the last three bases of the exon, which is part of the 5? splice region. Computational tools do not suggest an impact to splicin g. However, this information is not predictive enough to rule out pathogenicity. In summary, while the clinical significance of the p.Arg717Lys variant is uncer tain, these data suggest that it is more likely to be benign. - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 22, 2024 | - - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Apr 11, 2017 | - - |
Primary dilated cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | research | Klaassen Lab, Charite University Medicine Berlin | Jul 03, 2019 | - - |
LAMA4-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 04, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 05, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at